Abstract
There are a number of investigations regarding the relationship between fat-soluble vitamins and polymorphisms of their metabolic enzymes. Especially, polymorphisms of vitamin K metabolic enzymes are clinically adopted for warfarin administration. In this report, we show several recent investigations regarding polymorphisms of metabolic enzymes and binding proteins of vitamin A and vitamin E. Genome-wide association study revealed that polymorphisms of retinol-bind protein and transthyretin affected vitamin A status of Caucasian males. CYP26B1 is the metabolizing enzyme of retinoic acid. CYP26B1 polymorphism (rs2241057) has been reported to be associated with the development of Crohn's disease and atherosclerosis. CYP4F2 participates in ω-hydroxylation of vitamin E. Among children and adults with non-alcoholic fatty liver disease who were treated with vitamin E, the effect of CYP4F2 polymorphism on vitamin E status and the outcome were investigated. CYP4F2 polymorphism affected vitamin E pharmacokinetics but had no significant association with hepatic histological end points. It is expected that further studies will clarify the relationship between polymorphism of proteins related to fat-soluble vitamins and disorders.
